Overexpression of ERBB2 (which is also commonly referred to as HER2) has been detected in 10-30% of GC cases, with amplification of ERBB2 detected in 2-27% of GC cases [28–30] and ERBB2 mutations detected in 5% of GC cases [69]. Here, ERBB2 is linked to gastric cancer.